相关实验视频

Updated: Jul 23, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

通过mexiletine衍生尿素进行hERG立体选择性调制:分子对接研究,合成和生物评估

Gualtiero Milani¹, Roberta Budriesi², Elisa Tavazzani³

¹Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Bari, Italy.

Archiv der Pharmazie

|July 17, 2023

概括

研究人员研究了一种新的药物来源于mexiletine的长QT综合征 (LQTS). 该研究发现,该化合物的特定形式 - - 尿素8 - - 能够有效地打开hERG通道,并且没有任何不良心脏或肠道影响.

科学领域:

心血管药理学心血管药理学
分子心脏病学分子心脏病学
药物发现药物发现药物发现

背景情况:

长QT综合征 (LQTS) 是一种关键的心脏电生理学障碍,导致危及生命的心律失常.
目前对LQTS的治疗选择有限,需要开发新的治疗方法.
LQT2是一种常见的LQTS亚型,源于人类以太-to-go-go相关基因 (hERG) 的突变.

研究的目的:

为了研究在hERG通道上的素8素的立体选择性.
评估化合物8作为LQTS治疗剂的潜力.
在心脏和肠道组织中评估化合物8的安全性.

主要方法:

为了指导实验设计,进行了in silico预测.
在体外研究中评估了化合物8在hERG通道上的活性.
实体功能研究是在孤立的几内亚猪左心房,大动脉和大肠骨上进行的.

主要成果:

在体外研究表明,化合物8在hERG通道上的立体选择性活性.
化合物8的形表现出最显著的hERG通道开通活动.
活体研究显示,化合物8对心脏或肠道没有负担.

结论:

梅西利丁衍生尿素8显示立体选择性hERG通道开放活性.
化合物8具有良好的安全性,在体外模型中没有观察到心脏或肠道不良影响.
(R,S) - 8代表了开发新疗法用于先天性和药物诱导的LQTS的有希望的领先.

关键词:

在hERG频道.长时间QT综合征墨西哥墨西哥人分子对接的分子对接.尿素是一种尿素.

更多相关视频

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

相关概念视频

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...